Aims To clarify the frequency and severity of diabetic retinopathy in a group of people with Type 2 diabetes and chronic diabetic foot ulcers, and to compare visual acuity, levels of retinopathy and clinical significant macular oedema with a matched control group of people with Type 2 diabetes without a history of chronic diabetic foot ulcers.
Introduction
Chronic foot ulceration is a common and serious complication of diabetes and an expensive challenge for the healthcare system [1] . Typically, the condition is preceded by peripheral neuropathy, and micro-as well as macrovascular disease, which are often present at time of ulceration. The leading cause of registered blindness in the western world, diabetic retinopathy (DR), affects about one-quarter of white people with Type 2 diabetes, and within 20 years of the diagnosis >60% will develop DR [2] [3] [4] . Vision loss as a result of DR has several causes, including pre-retinal or vitreous haemorrhage, retinal detachment, neovascular glaucoma, macular oedema and capillary non-perfusion. The condition is associated with diabetic neuropathy and other microvascular complications [5, 6] . Despite an apparent reasonable covariation of pathological mechanisms between retinopathy and diabetic foot ulceration, only one previous study has addressed the prevalence and severity of DR in people with diabetic foot ulcers (DFUs) [7] .
The aim of the present real-life clinical study was to elucidate the frequency and severity of DR in a group of people with Type 2 diabetes and chronic DFUs. We compared visual acuity, levels of retinopathy and presence of clinical significant macular oedema in this group with a control group matched for age, sex and Type 2 diabetes duration but without a history of chronic DFUs.
Methods
The study was approved by the Regional Ethics Committee in Lund, Sweden and was carried out in accordance with the Declaration of Helsinki, as revised in 2000.
Correspondence to: Anders Sellman. E-mail: anders.sellman@med.lu.se Ninety white people with Type 2 diabetes and at least one full-thickness DFU below the ankle of >3 months' duration were consecutively recruited between 2003 and 2007 from a Diabetic Foot Clinic that applied international treatment guidelines [8] . Findings from eye examinations in these 90 people were compared with those from 180 white people with Type 2 diabetes but without a history of chronic DFUs (control group). Controls were matched for sex, age and diabetes duration.
Swedish National Diabetes Guidelines recommend eye examinations at least every third year in people without diabetic retinopathy, and more frequently (every 3-12 months) in those with eye lesions, depending on the severity. At the time of data collection the adherence to these timeline recommendations was >90% in our catchment area. Outcomes from all examinations were registered in the Helsingborg Hospital Diabetes Eye Registry, from which our control group was selected. At the time of selection only data regarding sex, age and diabetes duration were available for assessment by the investigators. People with longstanding DFUs routinely had eye examinations in connection with DFU treatment. Our matched controls were selected to have had a routine eye examination within 18 months of their matched comparison. In accordance with local recommendations, all people with non-healing DFUs should be referred to the diabetic foot clinic in the catchment area. None of the people in our control group had been referred to the diabetic foot clinic, according to the patients' registry.
At the time of eye examination the duration of the DFU was 4.8AE1.9 months and 74% of the ulcers were classified as Wagner grade 3 or higher. The mean DFU area was 3.2AE1.7 cm 2 .
Best corrected visual acuity was evaluated using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual chart in the DFU group and the Snellen chart in the control group [9] . The Snellen values were then mathematically translated to ETDRS values, using established formulas, 55 letters of the ETDRS chart then correspond to visual acuity 1.0 (6/6, 20/20, logMar 0.00) [9, 10] . Visual acuity is given for both eyes and presented as best and worst eye visual acuity.
Fundus photographs of seven standard fields were taken in pharmacological mydriasis by certified registered nurses using a Topcon digital fundus camera (TRC-IX, -IA, or -EX; Topcon, Tokyo, Japan). The photos were examined and graded using the Topcon Image-net system (Topcon). In the DFU group all photos were graded by the same senior consultant in ophthalmology (A.S.), who also re-evaluated the retinal pictures from the control group. Retinopathy was classified according to the alternative classification of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), in which total retinopathy levels were derived by giving those eyes with higher levels a greater weight; levels 1-5 are equal to no DR or mild non-proliferative DR, levels 6 and 7 to moderate non-proliferative DR in one or both eyes, levels 8 and 9 to severe non-proliferative DR in one or both eyes and level ≥10 to proliferative DR, new or old, in one or both eyes [11, 12] .
The ETDRS definition of clinical significant macular oedema was used to determine the presence or non-presence of clinical significant macular oedema [13] . The condition was considered present when oedema or hard exudates involved the fovea or was within 500 microns of the fovea, or when one disc area of oedema was present with at least a portion of it within one disc diameter from the macular centre.
Diagnosis of Type 2 diabetes was based on patient charts. Hypertension was considered present in people with resting systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg or already on blood pressure-lowering drugs at the time of the eye examination. HbA 1c and creatinine levels at the time of the eye examination were assessed from charts. HbA 1c measurements were performed using high-performance liquid chromatography according to clinical routines in the central laboratory of the hospital and are reported according to Diabetes Control and Complications Trial and International Federation of Clinical Chemistry standards. Estimated GFR (eGFR) was calculated from plasma creatinine using the modification of diet in renal disease equation [14] . Participants were grouped according to eGFR of ≤30, 31-60 and >60 ml/min/1.73m 2 . Diabetes treatment was categorized into three groups: no pharmacological intervention; only oral pharmacological treatment; insulin treatment.
Statistics
Statistical analyses were performed using SPSS version 22 (IBM, Chicago, Il, USA) and included all evaluable eyes. Shapiro-Wilk tests were used to confirm normal distribution, with all variables apart from visual acuity being normally distributed. Visual acuity is given as median and interquartile range, and all other continuous variables using mean AE SD. Mann-Whitney U-tests were used to compare differences in What's new?
• In our Scandinavian population with diabetes and chronic foot ulcers, <10% of people were free from diabetic retinopathy and >40% had pre-proliferative or proliferative diabetic retinopathy.
• Proliferative diabetic retinopathy in this population was more common in people with than those without chronic foot ulcers (31% vs 8%; P<0.001), despite similar diabetes duration.
• Chronic diabetic foot ulcers appeared to be linked to impaired visual acuity.
ª 2018 Diabetes UK visual acuity between groups, with chi-squared tests and Students t-tests otherwise used. We applied a multinominal logistic regression analysis to identify factors predicting retinopathy levels using the group of people with no or mild non-proliferative DR as the reference group. Age (decades), HbA 1c (10 mmol/mol), Type 2 diabetes duration (years), presence of chronic DFU, presence of hypertension, use of insulin, sex and eGFR (three groups) were entered into the model. A two-sided P-value <0.05 was taken to indicate statistical significance.
Results
Age, diabetes duration and sex distribution were similar in the two groups, suggesting an acceptable matching of control patients. The mean age was 69 years, diabetes duration just above 15 years, and almost two-thirds of the study population had reduced renal function, evaluated as eGFR. Deterioration of renal function was more pronounced in the DFU group. Insulin was more frequently included in the diabetes treatment regimens in the DFU group (79% vs 56%; P<0.01). HbA 1c levels did not differ between groups.
As shown in Fig. 1 , DR was more severe in the DFU group according to the alternative classification of the WESDR. Despite similar age and diabetes duration severe nonproliferative and proliferative DR was present in 41% of the people in the DFU group as compared to 15% in the control group (P<0.001). Only 6% of people in the DFU group were without DR as compared to 34% among controls. In insulin-treated people in the DFU group, fewer had no or mild non-proliferative DR as compared with those not treated with insulin (33 vs 68%; P=0.008). Conversely, in the control group fewer individuals with moderate nonproliferative, severe non-proliferative or proliferative DR were seen among non-insulin-treated as compared with insulin-treated people (11 vs 51%; P=0.0001). In a multinominal logistic regression analysis longer diabetes duration, presence of DFU and younger age were associated with higher retinopathy levels ( Table 2) .
Proliferative DR was more common in the DFU group (31% vs 8.4%; P<0.001), but the time from diabetes diagnosis to proliferative DR diagnosis did not differ between groups (15.5AE9.0 vs 18.6AE7.3 years; P=0.15).
Clinically significant macular oedema was or had been present in 40% of the DFU group as compared to 16% in the control group (P<0.001); however, time from diagnosis of diabetes to first visible presence of clinically significant macular oedema was similar in the two groups: 13.5AE8.7 years in the DFU group and 16.1AE4.6 years in the control group (P=0.17).
Among those with clinically significant macular oedema, presence of hypertension and use of insulin and HbA 1c levels were similar in the two groups, whereas chronic DFU was associated with a lower eGFR (50 vs 72 ml/min/1.73 m 2 ;
P=0.02).
Visual acuity was lower in the DFU group. The median (interquartile range) best eye visual acuity was 50 (42.75;55) EDTRS letters in the DFU group and 55 (52;55) in the control group (P<0.001). Similarly, the median (interquartile range) worst eye visual acuity was 40 (23;50) vs 53 (45;55) ETDRS letters (P<0.001). These differences in visual acuity were also present in the subgroup of people with no or mild non-proliferative DR, whereas in those with severe nonproliferative or proliferative DR visual acuity of the best, but not worst eye, differed between groups (Fig. 2) . Risk factors for poorer visual acuity of the best eye were male sex (P=0.004), presence of chronic DFU (P<0.001), older age (P=0.01) and duration of diabetes (P=0.024), whereas [16, 18, 19] . In our people with DFU, some type of DR was present in 94% and proliferative DPR in 31%. Hwang et al. [7] similarly reported 90% DR in a Korean population with DFU, with 55% presenting with proliferative DR. Diabetes duration was similar in their study to that in the present study (18.5 vs 16.9 
years).
Whereas Hwang et al. [7] used a control group with a mean age 10 years younger and with less prevalent hypertension and lower HbA 1c levels, we used a control group matched for sex, age and diabetes duration. This difference, as well as methodological differences in retinal examination, might explain the substantially higher DR occurrence in the control group (4.5 vs 66%) in the present study.
In the present study we observed a 3.9 times higher frequency of proliferative DR in people with chronic DFUs as compared to those of similar age and with similar diabetes duration but without a history of chronic DFUs. Furthermore, in our multinominal logistic regression model, people with chronic DFUs were 5.6 times more likely to have proliferative DR than no or mild DR. Nwanyanwu et al. [20] also reported an increased risk of developing proliferative DR in patients with DFU. In their population, presence of any DFU was associated with a 1.5 higher frequency of DR.
The importance of other microvascular complications as risk factors for foot ulceration is also well established. In 2016, Tomita et al. [21] reported that the combination of albuminuria and DR significantly increased the risk of developing DFU [21] . The importance of diabetic eye disease is further elucidated by a study identifying impaired vision (hazard ratio 6.92), DR (hazard ratio 6.42), male sex (hazard ratio 2.4) and microalbuminuria (hazard ratio 2.11) as the most important predictors for lower limb amputation in a 19-year follow-up of 1381 people with newly diagnosed Type 2 diabetes [22] . In the Seattle Foot Study, impaired vision [Snellen 20/40 (0.5)] was associated with a 1.48 (1.00- *** *** *** *** ** FIGURE 2 Visual acuity for the best and worst eye in the diabetic foot ulcer (DFU; dotted bars, n=90) and control group (grey bars, n=180). Data are given for the overall population as well as for subgroups of patients with no or mild non-proliferative diabetic retinopathy (DR; n=37 and 124), moderate non-proliferative DR (n=16 and 29) and severe non-proliferative or proliferative DR (n=37 and 27; P=0.058). Data are medians and interquartile ranges. *P<0.05, **P<0.01, ***P<0.001.
In the DFU group, 79% used insulin as compared to 56% in the control group. This might reflect more advanced disease progression in the DFU group, but, in terms of visual acuity, no differences could be seen between insulin and non-insulin users in either group. Renal function was lower in the DFU group but did not differ between insulin and non-insulin users. In a general US diabetes population, DR has been linked to more prevalent insulin prescriptions, e.g. 47% vs 27% in people without DR (odds ratio 3.2) [7] . In another study the prevalence of DR was 70% in people with Type 2 diabetes using insulin as compared to 39% of those not using insulin treatment [2] . In this respect, the present findings are consistent with these reports, although, in the present study population, insulin treatment seemed to be a weaker risk factor for DR than presence of chronic DFU, diabetes duration and HbA 1c . Our finding that presence of hypertension was associated with decreased risk of proliferative DR probably mirrors a potential protective effect of treatment with ACE-inhibitors or angiotension II receptor blockers [23] .
The present study has several limitations apart from its retrospective nature. Firstly, there was a lack of reliable assessment of other potential risk factors, such as neuropathy, peripheral vascular disease and smoking habits, in the control group. Secondly, the higher percentage of men may have affected our outcome, as in most DFU studies. Thirdly, our relatively small sample size may have limited the detection of differences between people with and without DFU.
Important strengths of this study include the rigorous and standardized measurements of retinopathy and visual acuity, consecutive inclusion of patients with chronic DFUs from a single general hospital catchment area, and matching of the control group.
In conclusion, in this northern European setting, almost all people with Type 2 diabetes and chronic DFUs had DR. Almost one-third had proliferative DR as compared to <10% in the matched control group. More advanced DR was accompanied by worse visual acuity.
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